Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Do‐Youn Oh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1663-9901; OpenAlex author ID A5059766169, A5112268597. Sources: ClinicalTrials.gov.

Their work

Papers
48 (first author 8, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
178
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 4 papers · 2018: 3 papers, 1 trial · 2019: 6 papers · 2020: 7 papers · 2021: 5 papers · 2022: 1 paper · 2023: 5 papers · 2024: 2 papers · 2025: 4 papers · 2026: 2 papers

Papers 48

  1. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  2. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  3. Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. First author DOI 10.1002/cpt.3528↗
  4. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Co-author DOI 10.1016/j.esmogo.2025.100158↗
  5. Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitiviti… Co-author DOI 10.1186/s12935-025-03671-8↗
  6. Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12964-025-02242-8↗
  7. Optimal timing of surgery after neoadjuvant treatment in borderline resectable pancreatic cancer. Co-author DOI 10.1002/jhbp.12049↗
  8. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. Co-author DOI 10.1177/17588359241290482↗
  9. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Co-author DOI 10.1002/jhbp.1050↗
  10. Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study. First author DOI 10.1007/s00330-022-09271-8↗
  11. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  12. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Last author DOI 10.1093/oncolo/oyad022↗
  13. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  14. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  15. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … First author DOI 10.1016/j.annonc.2021.01.070↗
  16. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. First author DOI 10.1136/jitc-2020-002068↗
  17. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗
  18. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancre… Co-author DOI 10.4143/crt.2020.928↗
  19. Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Co-author DOI 10.5009/gnl20070↗
  20. The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy. Last author DOI 10.1002/cam4.2677↗
  21. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2020.07.029↗
  22. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literat… Last author DOI 10.1097/mpa.0000000000001507↗
  23. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
  24. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  25. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prosp… Co-author DOI 10.2967/jnumed.119.226407↗
  26. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. Last author DOI 10.4143/crt.2019.183↗
  27. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. First author DOI 10.1001/jamaoncol.2019.1588↗
  28. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Co-author DOI 10.1002/jhbp.648↗
  29. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Last author DOI 10.1038/s41598-019-47330-1↗
  30. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  31. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗
  32. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korea… Co-author DOI 10.1177/1758835919871126↗
  33. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  34. Correction: Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.24175↗
  35. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. Co-author DOI 10.2214/ajr.17.18310↗
  36. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  37. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradioth… Co-author DOI 10.1007/s10147-017-1129-7↗
  38. Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. Co-author DOI 10.18632/oncotarget.21861↗
  39. Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer. Co-author PMID 28952226↗
  40. More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. First author DOI 10.1371/journal.pone.0145692↗
  41. Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. Co-author DOI 10.21873/anticanres.11125↗
  42. The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.4143/crt.2014.292↗
  43. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. First author DOI 10.4143/crt.2015.226↗
  44. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. First author DOI 10.1371/journal.pone.0139749↗
  45. Prognostic value of splenic artery invasion in patients undergoing adjuvant chemoradiotherapy after distal pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.4143/crt.2014.025↗
  46. The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. Co-author DOI 10.1016/j.jpainsymman.2013.08.017↗
  47. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysi… Co-author DOI 10.1007/s10637-011-9651-3↗
  48. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analy… Co-author DOI 10.1007/s00280-011-1584-1↗

Trials 1

  1. Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic… Principal investigator NCT03572400↗

Closest collaborators

The 25 strongest of 178 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Young Jang · 13 shared papers, 2015–2025 · strength 1.40
  2. Wooil Kwon · 10 shared papers, 2017–2026 · strength 1.30
  3. Yung‐Jue Bang · 16 shared papers, 2011–2021 · strength 1.24
  4. Sang Hyub Lee · 7 shared papers, 2019–2025 · strength 1.22
  5. Teresa Mercade Macarulla · 10 shared papers, 2019–2026 · strength 1.16
  6. Eui Kyu Chie · 11 shared papers, 2015–2024 · strength 1.11
  7. Kyung-Hun Lee · 10 shared papers, 2011–2023 · strength 0.82
  8. Eileen Mary O'Reilly · 6 shared papers, 2019–2026 · strength 0.73
  9. Michele Reni · 7 shared papers, 2019–2023 · strength 0.73
  10. Ji Kon Ryu · 5 shared papers, 2018–2024 · strength 0.66
  11. Eric Van Cutsem · 6 shared papers, 2019–2023 · strength 0.59
  12. Joon Oh Park · 7 shared papers, 2018–2022 · strength 0.57
  13. Chung‐Pin Li · 5 shared papers, 2020–2023 · strength 0.54
  14. Seock‐Ah Im · 9 shared papers, 2011–2021 · strength 0.52
  15. Kyubo Kim · 7 shared papers, 2015–2020 · strength 0.51
  16. Sun‐Whe Kim · 7 shared papers, 2015–2021 · strength 0.50
  17. Hongbeom Kim · 4 shared papers, 2019–2023 · strength 0.48
  18. Kyu‐pyo Kim · 3 shared papers, 2019–2025 · strength 0.46
  19. Jill Lacy · 3 shared papers, 2020–2026 · strength 0.46
  20. Mariano Ponz‐Sarvisé · 2 shared papers, 2025–2026 · strength 0.46
  21. Won‐Gun Yun · 2 shared papers, 2024–2025 · strength 0.45
  22. Andrew Eugene Hendifar · 4 shared papers, 2020–2021 · strength 0.40
  23. Margaret A. Tempero · 4 shared papers, 2020–2021 · strength 0.40
  24. Hye‐Sol Jung · 2 shared papers, 2024–2026 · strength 0.40
  25. Jens Thomas Siveke · 2 shared papers, 2023–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.